Exclusive: Former FDA head Stephen Hahn joins radiopharmaceuticals startup

Plus: FDA "uncertainty" forces Krystal Biotech to shutter cancer drug trial

August 22, 2025 Check out STAT+

Sponsored By

GRAEME JENNINGS/POOL/AFP via Getty Images STAT+ | Former FDA head Stephen Hahn joins radiopharmaceuticals startup as CEO Nucleus RadioPharma hopes to expand access to therapies in a field that has proven challenging for other companies. By Allison DeAngelis STAT+ | Gilead's Kite Pharma acquires Interius BioTherapeutics for $350 million The purchase by Kite is latest move in a race to develop simpler, safer, and more scalable cell therapies. By Jason Mast Opinion: The trauma of illness can last long after the body has healed Medicine overlooks the psychological toll of medical illness. Healing must involve helping people repair their relationship with their bodies. By Alexandra Kutnick Jacquelyn Martin/AP STAT+ | FDA 'uncertainty' forces Krystal Biotech to shutter cancer drug trial  The decision follows the agency's rejection of a similar drug developed by Replimune Group earlier this month. By Adam Feuerstein

More around STAT

---

In case you missed it Ozempic linked to reduced cancer risk, Newsweek Treatment that can double bladder cancer survival rates approved by UK's NHS and available to 1,000 patients in England, the Guardian Exclusive: Major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, FDA finds, STAT Why direct-to-consumer sales are unlikely to significantly lower drug costs, STAT

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser